Diacerein as the Drug of Choice in the Therapy of Knee Osteoarthritis With Secondary Recurrent Synovitis

Udovika, M.I. Udovika

doi:10.14412/1995-4484-2015-614-618

Cited by 3 publications

(1 citation statement)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1 ное статистически значимое уменьшение толщины СО и объема синовиального выпота в полости сустава: с 6,2±2,4 до 2,8±1,2 мм (р=0,001) и с 36,88±8,73 до 5,86±3,10 мл (р=0,00006) соответственно по сравнению с показателями в контрольной группе: с 5,7±2,8 до 3,6±2,8 (р=0,05) мм и с 37,66±8,21 до 21,70±6,12 мл (р=0,001). Эффект терапии достигнут у 100% пациентов, леченных Д, и только у 43% больных контрольной группы [10]. В другом 6-месячном исследовании данными магнитно-резонансной томографии (МРТ) также подтверждено противовоспалительное действие Д. В этом исследовании 20 пациентов 1-й группы принимали Д и НПВП при необходимости, а 20 пациентов 2-й группытолько НПВП.…”

unclassified

Efficacy and safety of diacerein in patients with knee osteoarthritis

Алексеева¹,

Кашеварова²,

Таскина³

et al. 2017

RJTAO

View full text Add to dashboard Cite

Диацереин (Д) относится к медленно действующим симптоматическим средствам, обладает оригинальным механизмом действия и широко используется в России и многих странах мира для базисной медикаментозной терапии остеоартрита (ОА). Способность препарата влиять на основные симптомы и прогрессирование ОА показана в ряде хорошо организованных клинических исследований. Цель-оценить эффективность и безопасность Д у пациентов с ОА коленных суставов.

show abstract

unclassified

Efficacy and safety of diacerein in patients with knee osteoarthritis

Алексеева¹,

Кашеварова²,

Таскина³

et al. 2017

RJTAO

View full text Add to dashboard Cite

show abstract

Pleiotropic effects of diacerein in comorbid patients with osteoarthritis

Belyaeva

Mazurov

2022

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

The article presents an analysis of the therapeutic effect of the drug diacerein (D), which has been used in osteoarthritis (OA) for more than 20 years and is included in the clinical guidelines of the Association of Rheumatologists of Russia (2021) and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal diseases (ESCEO, 2019) for the treatment of OA. The main pathogenic effect of D in OA is to suppress the synthesis of interleukin 1, stimulate the production of articular cartilage proteoglycans, and slow down abnormal remodeling of the subchondral bone. The advantages of D in the treatment of patients with OA and comorbidities are presented – a prolonged anti-inflammatory and analgesic effect and good tolerability. These properties of D allow to control the symptoms of OA and improve the quality of life of patients. The structure-modifying effect of D is based on its ability to stimulate the synthesis of articular cartilage proteoglycans with long-term use and prevent abnormal remodeling of the subchondral bone, which leads to a decrease in the risk of OA progression and a delay in total joint arthroplasty. An important advantage of D is its positive metabolic effect in patients with type 2 diabetes mellitus and obesity, which is associated with the ability of D to reduce the level of glycated hemoglobin and body mass index. Data are presented on the absence of adverse cardiovascular effects when using D, which allows us to recommend its use in patients with OA who have comorbid cardiovascular diseases, as well as contraindications for non-steroidal anti-inflammatory drugs.

show abstract

Substantiation of the method of local deep hypothermia for the relief of synovitis of the knee joint in patients with osteoarthritis

Tereshenkov,

Shevelev,

Zagorodniy

et al. 2023

Medical Journal of the Russian Federation

View full text Add to dashboard Cite

BACKGROUND: In patients with osteoarthritis, the long course of synovitis changes the nature of the inflammatory process, it becomes more resistant and resistant to a number of therapeutic techniques. In the arsenal of a practicing doctor, there are no reliable and affordable therapeutic methods that reliably provide relief of synovitis in the knee joint and objectively monitor the effectiveness of the therapy. Among the numerous methods of application in the treatment of diseases and injuries of the musculoskeletal system, low-molecular technologies with anti-inflammatory and analgesic effects are distinguished. One of these methods is local deep hypothermia. AIM: To substantiate the use of different low-temperature modes of local deep hypothermia in patients with knee osteoarthritis aggravated by synovitis, to study clinical efficacy and safety. MATERIALS AND METHODS: The study included 90 patients with osteoarthritis of the knee joints, burdened with synovitis. To determine the therapeutic parameters of local deep hypothermia, all patients were divided into three groups of 30 people. The effectiveness of the performed local deep hypothermia was assessed by the dynamics of the algofunctional Leken index, the intensity of joint pain on a 100-point Visual Analogue Scale (VAS) in millimeters and a decrease in the need for nonsteroidal anti-inflammatory drugs (NSAIDs). RESULTS: Technical and clinical parameters have been developed for carrying out the local deep hypothermia technique: area, cooling depth, rate of heat removal from the joint, duration of reproduction and number of procedures. Against the background of the performed local deep hypothermia, patients in three groups showed significant positive dynamics on the VAS and algofunctional Leken index, and in all three groups the difference between the initial and final values of these parameters was statistically significant (p 0.001). The use of local deep hypothermia allowed a significant part of patients to refuse to take NSAIDs, or to reduce the need to 50 mg and take episodically according to need. In our study, we did not record a recurrence of synovitis in all three groups during the first 3 months, which was 100%. After 12 months, the duration of remission in group I was 10.0%, in group II patients 73.3% and in group III patients 86.6%. CONCLUSION: Local deep hypothermia improves the effectiveness of synovitis treatment and can be recommended as an independent method for the treatment of patients with osteoarthritis of the knee aggravated by synovitis. The recommended local deep hypothermia exposure is 90 min, which allows for the longest period of remission of synovitis in the knee joint.

show abstract

Diacerein as the Drug of Choice in the Therapy of Knee Osteoarthritis With Secondary Recurrent Synovitis

Cited by 3 publications

References 17 publications

Efficacy and safety of diacerein in patients with knee osteoarthritis

Efficacy and safety of diacerein in patients with knee osteoarthritis

Pleiotropic effects of diacerein in comorbid patients with osteoarthritis

Substantiation of the method of local deep hypothermia for the relief of synovitis of the knee joint in patients with osteoarthritis

Contact Info

Product

Resources

About